Ardelyx (NASDAQ:ARDX) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Ardelyx (NASDAQ:ARDX) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02), FiscalAI reports. Ardelyx had a negative net margin of 12.35% and a negative return on equity of 35.57%. The firm had revenue of $120.88 million during the quarter, compared to the consensus estimate of $121.03 million. During the same quarter last year, the firm earned ($0.08) earnings per share. The business’s revenue for the quarter was up 34.3% compared to the same quarter last year.

Here are the key takeaways from Ardelyx’s conference call:

• Q2 product revenue reached a record $118 million, up 31% year over year, with IBSRELA revenue increasing 33% to $86.2 million and XPHOZAH revenue rising 27% to $31.9 million.
• IBSRELA faced more stringent payer prior authorizations and step edits, slowing new-patient starts despite record demand, refills, and total prescriptions. The company lowered 2026 IBSRELA revenue guidance to $350 million-$370 million.
• Ardelyx reiterated XPHOZAH 2026 revenue guidance of $110 million-$120 million but withdrew its longer-term $750 million revenue target while it assesses post-TDAPA market dynamics and upcoming dialysis payment policies.
• Management is expanding field reimbursement and commercial support for IBSRELA, including doubling reimbursement staff, increasing the sales force to 144 representatives, and further promoting the IBSRELA Pharmacy Network to improve fulfillment and adherence.
• The company ended the quarter with $281.8 million in cash, revised 2026 operating-expense guidance to below $500 million, and maintained its expectation of achieving profitability in 2027 while advancing its pipeline and tenapanor patent estate.

Ardelyx Stock Performance

Shares of NASDAQ:ARDX opened at $4.00 on Friday. The company’s 50 day simple moving average is $5.37 and its 200 day simple moving average is $6.08. The stock has a market capitalization of $988.12 million, a price-to-earnings ratio of -18.18 and a beta of 0.70. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.49 and a quick ratio of 3.28. Ardelyx has a 1 year low of $3.90 and a 1 year high of $8.40.

Insider Buying and Selling at Ardelyx

In related news, insider Mike Kelliher sold 7,248 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $6.27, for a total transaction of $45,444.96. Following the completion of the sale, the insider directly owned 357,418 shares in the company, valued at $2,241,010.86. This represents a 1.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Duane Foster sold 7,998 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $6.27, for a total value of $50,147.46. Following the completion of the sale, the insider directly owned 417,972 shares in the company, valued at $2,620,684.44. This trade represents a 1.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 24,572 shares of company stock valued at $154,066 over the last 90 days. Corporate insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Ardelyx

A number of hedge funds have recently made changes to their positions in the stock. State of Wyoming acquired a new position in Ardelyx during the 4th quarter worth approximately $74,000. WINTON GROUP Ltd acquired a new position in shares of Ardelyx during the fourth quarter worth $79,000. Jain Global LLC acquired a new position in shares of Ardelyx during the third quarter worth $74,000. Sargent Investment Group LLC bought a new position in shares of Ardelyx in the 4th quarter valued at $82,000. Finally, Steward Partners Investment Advisory LLC boosted its holdings in shares of Ardelyx by 81.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 14,021 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 6,293 shares in the last quarter. 58.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ARDX shares. TD Cowen dropped their target price on Ardelyx from $13.00 to $10.00 and set a “buy” rating for the company in a report on Friday. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Ardelyx in a research note on Friday. Zacks Research lowered shares of Ardelyx from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. LADENBURG THALM/SH SH assumed coverage on shares of Ardelyx in a research note on Tuesday, June 16th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, BTIG Research decreased their target price on shares of Ardelyx from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $15.30.

Ardelyx News Roundup

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Second-quarter revenue increased 34.3% year over year to approximately $120.9 million, indicating continued commercial growth despite missing the revenue estimate slightly. Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: BTIG Research maintained a Buy rating on ARDX, suggesting substantial long-term upside potential even after reducing its price target from $17 to $14. BTIG Research price target update
• Neutral Sentiment: Ardelyx’s Q2 earnings call and business update provided additional discussion of operating performance and company priorities, but the available report does not identify a specific new catalyst driving the stock. Ardelyx Q2 2026 Earnings Call Transcript
• Negative Sentiment: Ardelyx reported a second-quarter loss of $0.07 per share, worse than the expected loss of $0.05, although it improved from a $0.08 loss in the year-ago quarter. Revenue of $120.88 million also narrowly missed estimates of approximately $121.0 million. Ardelyx Reports Q2 Loss, Lags Revenue Estimates
• Negative Sentiment: Zacks added ARDX to its Rank #5, or Strong Sell, list, adding to near-term pressure from the earnings miss and the company’s continuing negative profitability metrics. New Strong Sell Stocks for August 7th
• Negative Sentiment: The lower BTIG price target reflects reduced near-term expectations, even though the firm retained its Buy rating. BTIG Research price target update

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio?renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.